Inscrição na biblioteca: Guest
Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa
Critical Reviews™ in Immunology
Fator do impacto: 1.352 FI de cinco anos: 3.347 SJR: 0.657 SNIP: 0.55 CiteScore™: 2.19

ISSN Imprimir: 1040-8401
ISSN On-line: 2162-6472

Volumes:
Volume 39, 2019 Volume 38, 2018 Volume 37, 2017 Volume 36, 2016 Volume 35, 2015 Volume 34, 2014 Volume 33, 2013 Volume 32, 2012 Volume 31, 2011 Volume 30, 2010 Volume 29, 2009 Volume 28, 2008 Volume 27, 2007 Volume 26, 2006 Volume 25, 2005 Volume 24, 2004 Volume 23, 2003 Volume 22, 2002 Volume 21, 2001 Volume 20, 2000 Volume 19, 1999 Volume 18, 1998 Volume 17, 1997 Volume 16, 1996 Volume 15, 1995 Volume 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.v30.i4.30
pages 345-386

Tumor Antigen Presentation by Dendritic Cells

Troels R. Petersen
Malaghan Institute of Medical Research, Wellington, New Zealand
Nina Dickgreber
Malaghan Institute of Medical Research, Wellington, New Zealand
Ian F. Hermans
Malaghan Institute of Medical Research, Wellington, New Zealand

RESUMO

Tumor cells are generally regarded as poor stimulators of naive T cells. In contrast, dendritic cells (DCs) are highly specialized in this function, and are therefore likely to be important intermediaries in the process of stimulating T cell responses to tumors. While providing solid evidence that DCs participate in antitumor immunity has proved difficult, several lines of evidence point in this direction. First, animal models involving bone marrow chimeras have shown that cells of hematopoeitic origin are required to elicit T cell responses to whole-tumor vaccines. Second, compared with other cells of hematopoeitic origin, DCs are particularly well-equipped to cross-present exogenous antigens to CD8+ T cells, a critical function if intermediary cells are involved. Third, tumor-infiltrating DCs purified from tumor samples have the capacity to cross-present tumor antigens in vitro. Finally, priming of anti-tumor T cell responses can be abrogated in new in vivo models in which DCs can be specifically depleted. It is therefore significant that DCs in cancer patients are often kept in an immature or dysfunctional state, thereby preventing stimulation of tumor-specific T cells. This review describes the different steps required for DCs to elicit T cell responses to tumor-associated antigens, and highlights processes that are amenable to intervention as therapy. We conclude that effective anti-tumor activity may be dependent on the ability to re-program DCs resident in the host, perhaps even when transferred autologous DCs generated ex vivo are used as vaccines. In this context, recruiting the activity of cells of the innate immune system to condition host DCs may help elicit more effective T cell-mediated responses.


Articles with similar content:

Mycobacterium tuberculosis-Specific CD8+ T Cells and Their Role in Immunity
Critical Reviews™ in Immunology, Vol.26, 2006, issue 4
Samuel M. Behar, Joshua S. M. Woodworth
The Phenotype and Function of Lung Dendritic Cells
Critical Reviews™ in Immunology, Vol.25, 2005, issue 6
Allison T. Thiele, Kena A. Swanson, Tina L. Sumpter, Tonya J. Webb, David S. Wilkes
Role of Dendritic Cells in Host−Mycobacterium Bovis BCG Interactions
Forum on Immunopathological Diseases and Therapeutics, Vol.6, 2015, issue 3-4
Krzysztof Krawczyk, Magdalena Kowalewicz-Kulbat, Wieslawa Rudnicka
T-Cell Adoptive Therapy of Tumors: Mechanisms of Improved Therapeutic Performance
Critical Reviews™ in Immunology, Vol.21, 2001, issue 1-3
Brian J. Czerniecki, Jorgen Kjaergaard, Liaomin Peng, Peter A. Cohen, Gary K. Koski, James H. Finke, Suyu Shu, Gregory E. Plautz
Dendritic Cell Cross Talk with Innate and Innate-like Effector Cells in Antitumor Immunity: Implications for DC Vaccination
Critical Reviews™ in Immunology, Vol.34, 2014, issue 6
I. Jolanda M. de Vries, Jasper J. P. van Beek, Annette E. Skold, Stanleyson V. Hato, Florian Wimmers